Results

This is a permanent results page for your analyzed data. Please save the link in your browser's address bar.

GEN3VA Reports for these tags

DRUGS_BD2K_LINCS_DCIC_COURSERA

SOFT file
Title / Description Expression data comparing azacitidine and decitabine in non-small cell lung cancer lines
Accession GSE29077
Summary Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in solid tumors. To better understand the mechanism of action of these drugs, we examined the effects of AZA and DAC in a panel of non-small cell lung cancer (NSCLC) cell lines. Of 5 NSCLC lines tested in a cell viability assay, all were sensitive to AZA (EC50 of 1.8–10.5 µM), while only H1299 cells were equally sensitive to DAC (EC50 of 5.1 µM). In the relatively DAC-insensitive cell line A549, both AZA and DAC caused DNA methyltransferase I depletion and DNA hypomethylation; however, only AZA significantly induced markers of DNA damage and apoptosis, suggesting that mechanisms in addition to, or other than, DNA hypomethylation are important for AZA-induced cell death. Cell cycle analysis indicated that AZA induced an accumulation of cells in sub-G1 phase, whereas DAC mainly caused an increase of cells in G2/M. Gene expression analysis of AZA- and DAC-treated cells revealed strikingly different profiles, with many genes distinctly regulated by each drug. In summary, while both AZA and DAC caused DNA hypomethylation, distinct effects were demonstrated on regulation of gene expression, cell cycle, DNA damage, and apoptosis.
Organism Homo sapiens
Platform GPL571
Normalized False
Parsed SOFT file
Metadata
Differential expression method Characteristic Direction
Cutoff 500
Drug_name Azacitidine
Smiles C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Drugbank_id DB00928
Pubchem_cid 9444
Cell_type A549
Organism human
Visualizations
Principal Component Analysis
Hierarchical clustering
External Links and Downloads
Gene lists Enrichr L1000CDS2 PAEA Crowdsourcing
Up
Down
Combined